Skip to main content
. 2019 Jan 4;11:1. doi: 10.1186/s13073-018-0611-9

Fig. 6.

Fig. 6

Monitoring response in metastatic breast cancer patients using NG-TAS. a Example of patient monitoring during treatment using direct NG-TAS in ctDNA. There are four mutations detected in more than one sample: GATA3 (F431 fs), PIK3CA (E542K), CDKN1B (N124 fs) and PTEN (137-139del). The mutations called more than once in the longitudinal samples are shown including the tumour and plasma samples. The arrow indicates the time of the disease considered as RECIST progressive disease. T indicates tumour samples, and SP indicates screening plasma sample which was collected prior to the treatment. b Example of patient monitoring during treatment using NGS library material for NG-TAS. This patient had a stable disease during the whole treatment period. There are three mutations detected, including MAP3K1 (E303 frame shift), hotspot mutations PIK3CA (E545K) and TP53 (R141H and P46fs). T indicates tumour samples